Trends in Cardiovascular Medicine最新文献

{"title":"Editorial commentary: Epicardial Adipose Tissue and Heart Failure.","authors":"Sunil Upadhaya, Thierry H. Le Jemtel","doi":"10.1016/j.tcm.2025.02.008","DOIUrl":"10.1016/j.tcm.2025.02.008","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 5","pages":"Pages 339-340"},"PeriodicalIF":7.3,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143532194","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac tumors: Updated classifications and main clinico-pathologic findings","authors":"Domenico Corradi ,&nbsp;Pedro R. Moreno ,&nbsp;Mohamed Rahouma ,&nbsp;Vivian M. Abascal ,&nbsp;Debora Guareschi ,&nbsp;Alessandro Tafuni ,&nbsp;Valentina Grazioli ,&nbsp;Alessandro Palumbo ,&nbsp;Giampaolo Niccoli ,&nbsp;Roberto Lorusso","doi":"10.1016/j.tcm.2025.01.005","DOIUrl":"10.1016/j.tcm.2025.01.005","url":null,"abstract":"<div><div>This review article – which is devoted to a wide range of physicians, e.g., pathologists, clinicians, radiologists, and general practitioners – is an up-to-date clinico-pathological description of cardiac tumours. Although rare, cardiac tumours are key components in oncology practice since both their early diagnosis and appropriate management denote urgent needs. Primary cardiac tumours (PCTs) are categorized in recent WHO classifications as well as in other scientific contributions. Their incidence is around 0.02 % while their prevalence is between 0.001 % and 0.03 %. Among PCTs, benign lesions account for 85 % of cases, while malignant neoplasms for 15 %. Compared to PCTs, secondary cardiac tumours are 20–30-fold more common. The most frequent PCTs in adulthood are papillary fibroelastoma and cardiac myxoma, while, in childhood, cardiac rhabdomyoma. Heart metastases may occur through direct extension, or, indirectly, via bloodstream, lymphatics or intracavitary diffusion. Thoracic cancers (e.g. from pleura, lung, breast) are the most frequent cause of cardiac metastasis followed by oesophageal and haematological malignancies. Symptoms of PCTs (e.g. arrhythmias, dyspnoea, chest discomfort, syncope) are usually the result of both their regional involvement and location. Non-invasive imaging techniques (e.g. echocardiography, MRI, CT) and biopsy are key means in delineating tumour characteristics, size, and adjacent structure involvement. Most PCTs require surgery, which is recommended to prevent life-threatening complications. While many benign cardiac neoplasms may be completely resected, the treatment of choice for malignant PCTs and metastases is a combination of surgery, radio- and/or chemotherapy, as well as new alternative treatments, which may prolong survival in a small patient subset.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 5","pages":"Pages 297-308"},"PeriodicalIF":7.3,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Uncovering the role of prokineticin pathway on Epicardial Adipose Tissue (EAT) development and EAT-associated cardiomyopathy","authors":"Martina Vincenzi ,&nbsp;Canan G. Nebigil","doi":"10.1016/j.tcm.2025.02.006","DOIUrl":"10.1016/j.tcm.2025.02.006","url":null,"abstract":"<div><div>Epicardial adipose tissue (EAT), a unique fat depot surrounding the heart, plays a multifaceted role in glucose and lipid metabolism, thermogenesis, and the secretion of bioactive molecules that influence cardiac structure and function. Its proximity to the myocardium allows it to contribute directly to CVDs, including coronary artery disease, arrhythmias, and heart failure. In particular, excessive EAT has emerged as a significant factor in heart failure with preserved ejection fraction (HFpEF), the most common form of heart failure, especially in individuals with obesity and diabetes. Traditional metrics like body mass index (BMI) fail to capture the complexities of visceral fat, as patients with similar BMIs can exhibit varying CVD risks. EAT accumulation induces mechanical stress and fosters a pro-inflammatory and fibrotic environment, driving cardiac remodeling and dysfunction.</div><div>Pharmacological modulation of EAT has shown promise in delivering cardiometabolic benefits. Recent advancements in diabetes therapies, such as SGLT2 inhibitors and GLP-1 receptor agonists, and antilipidemic drugs have demonstrated their potential in reducing pro-inflammatory cytokine production and improving glucose regulation, which directly influences EAT. These discoveries suggest that EAT could be a significant therapeutic target, though further investigation is necessary to elucidate its role in HFpEF and other CVDs.</div><div>Recent advances have identified the prokineticin/PKR1 signaling pathway as pivotal in EAT development and remodeling. This pathway regulates epicardial progenitor cells (EPDCs), promoting angiogenesis while reducing EAT accumulation and metabolic stress on the heart, particularly under high-calorie conditions. Prokineticin, acting through its receptor PKR1, limits visceral adipose tissue growth, enhances insulin sensitivity, and offers cardioprotection by reducing oxidative stress and activating cellular survival pathways. In this review, we provide a comprehensive analysis of EAT's role in CVDs, explore novel therapeutic strategies targeting EAT, and highlight the potential of prokineticin signaling as a promising treatment for HFpEF, obesity, and diabetes.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 5","pages":"Pages 328-338"},"PeriodicalIF":7.3,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter edge-to-edge repair for mitral regurgitation","authors":"Philipp von Stein ,&nbsp;Christos Iliadis","doi":"10.1016/j.tcm.2025.02.004","DOIUrl":"10.1016/j.tcm.2025.02.004","url":null,"abstract":"<div><div>Mitral valve transcatheter edge-to-edge repair (M-TEER) has emerged as a transformative therapy for mitral regurgitation (MR), addressing the unmet needs of patients unsuitable for surgery. Landmark trials such as EVEREST II, COAPT, and MITRA-FR have established the safety and efficacy of M-TEER, in both patients with primary (PMR) and secondary MR (SMR). Recent trials, including RESHAPE-HF2 and MATTERHORN, have expanded our understanding and refueled discussions regarding patient selection and appropriate treatment indications in SMR. These trials have also contributed to the discussion regarding SMR phenotypes most appropriate for M-TEER. This review summarizes the evidence from pivotal trials, discusses patient selection, device advancements, potential future directions, and outlines ongoing trials that may shape future clinical practice.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 5","pages":"Pages 320-325"},"PeriodicalIF":7.3,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiac implantable electronic device infection","authors":"Simon Christie ,&nbsp;Michael McGregor ,&nbsp;Andrew D. Krahn","doi":"10.1016/j.tcm.2025.02.001","DOIUrl":"10.1016/j.tcm.2025.02.001","url":null,"abstract":"<div><div>Cardiac implantable electronic device infections (CIEDI) are an important complication of device implantation associated with significant morbidity, mortality, and cost to the healthcare system. Identifying patients at high risk of device infection is paramount to improving decision making. This includes selecting appropriate devices and implementing adjunctive infection prevention measures, such as antimicrobial envelopes. In addition to meticulous antiseptic surgical technique, several other procedure-related practices can help reduce the risk of device infection. Developing expert centers with multidisciplinary teams capable of device extraction is important to manage patients with CIEDI. In this review, we aim to provide the reader with a succinct overview of CIEDI and summarize new evidence for risk assessment, prevention, diagnosis, and infection management.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 5","pages":"Pages 310-316"},"PeriodicalIF":7.3,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143416272","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atrial fibrillation burden and management in cardiomyopathies: Current evidence and unmet needs","authors":"Alexios S. Antonopoulos ,&nbsp;Alexandros Kasiakogias ,&nbsp;Alexandrina Kouroutzoglou ,&nbsp;Maria Touloupaki ,&nbsp;Alexandros Briasoulis ,&nbsp;Efstathios Papatheodorou ,&nbsp;Angelos G. Rigopoulos ,&nbsp;Dimitra Antonakaki ,&nbsp;Aggeliki Laina ,&nbsp;Konstantinos Tsioufis ,&nbsp;Charalambos Vlachopoulos ,&nbsp;George Lazaros","doi":"10.1016/j.tcm.2025.01.007","DOIUrl":"10.1016/j.tcm.2025.01.007","url":null,"abstract":"<div><div>Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in patients with cardiomyopathies and its clinical management presents a significant challenge. The prevalence of AF varies among cardiomyopathies, with hypertrophic (HCM) and dilated cardiomyopathy (DCM) associated with higher rates of AF. Presence of AF portends increased risk for thromboembolism, heart failure, and cardiovascular morbidity and mortality in patients with cardiomyopathy. The complex genetic substrate in DCM and non-dilated left ventricular cardiomyopathy (NDLVC) contribute to the heterogeneity of AF burden and its sequelae among cardiomyopathy genotypes, necessitating genotype-tailored approach in AF screening and management. Given the lack of validation of traditional risk scores for AF in cardiomyopathies, current clinical recommendations emphasize the importance of comprehensive risk stratification for AF, monitoring for AF, and early initiation of oral anticoagulation for brief AF episodes in specific cardiomyopathy subtypes such as hypertrophic or amyloid cardiomyopathy. AF management includes antiarrhythmic drugs, interventional therapies such as catheter ablation, mitral valve replacement when necessary, and lifestyle modifications to attenuate AF burden and improve quality of life. This review summarizes the current knowledge on the clinical significance, prognostic implications, and treatment of AF among different cardiomyopathy subtypes. We underscore the paradigm shift in AF management advocating for an individualized, subtype-specific, and genotype-aware approach to AF in cardiomyopathies, which is instrumental in improving prognosis and patient-centric care.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 5","pages":"Pages 284-293"},"PeriodicalIF":7.3,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial commentary: Cardiac implantable electronic device infection: Prevention is better than cure","authors":"Antoine Da Costa,&nbsp;Karim Benali","doi":"10.1016/j.tcm.2025.02.002","DOIUrl":"10.1016/j.tcm.2025.02.002","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 5","pages":"Pages 317-319"},"PeriodicalIF":7.3,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143411528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quinidine for ventricular arrhythmias: A comprehensive review","authors":"Redwane Rakza ,&nbsp;Pierre Groussin ,&nbsp;Karim Benali ,&nbsp;Nathalie Behar ,&nbsp;Philippe Mabo ,&nbsp;Dominique Pavin ,&nbsp;Christophe Leclercq ,&nbsp;Jackson J. Liang ,&nbsp;Raphaël P. Martins","doi":"10.1016/j.tcm.2024.07.003","DOIUrl":"10.1016/j.tcm.2024.07.003","url":null,"abstract":"<div><div>Quinidine, the first antiarrhythmic drug, was widely used during the 20th century. Multiple studies have been conducted to provide insights into the pharmacokinetics and pleiotropic effects of Class Ia antiarrhythmic drugs. However, safety concerns and the emergence of new drugs led to a decline in their use during the 1990s.</div><div>Despite this, recent studies have reignited the interest in quinidine, particularly for ventricular arrhythmias, where other antiarrhythmics have failed. In conditions such as Brugada syndrome, idiopathic ventricular fibrillation, early repolarization syndrome, short QT syndrome, and electrical storms, quinidine remains a valuable asset. Starting from the European and American recommendations, this comprehensive review aimed to explore the various indications for quinidine and the studies that support its use. We also discuss the potential future of quinidine, including the necessary research to optimize its use and patient selection. Additionally, it addresses the imperative task of mitigating the iatrogenic burden associated with quinidine usage and confronts the challenge of ensuring drug accessibility.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Pages 73-81"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141846599","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coronary drug-coated balloons: A comprehensive review of clinical applications and controversies","authors":"Muzamil Khawaja ,&nbsp;Michael Britt ,&nbsp;Affan Rizwan ,&nbsp;Jocelyn Abraham ,&nbsp;Taylor Nguyen ,&nbsp;Uzair Munaf ,&nbsp;Muhammad Asad Khan ,&nbsp;Hassaan Arshad ,&nbsp;Muhamed Munye ,&nbsp;Noah Newman ,&nbsp;Alfonso Ielasi ,&nbsp;Simon Eccleshall ,&nbsp;Vassilios S. Vassiliou ,&nbsp;Ioannis Merinopoulos ,&nbsp;Bernardo Cortese ,&nbsp;Chayakrit Krittanawong","doi":"10.1016/j.tcm.2024.08.006","DOIUrl":"10.1016/j.tcm.2024.08.006","url":null,"abstract":"<div><div>Drug-coated balloons have emerged as a promising therapeutic option in the treatment of cardiovascular disease. This review article provides an overview of the concept of drug-coated balloons and their clinical applications in both de novo and treated coronary artery disease. A summary of key clinical trials and registry studies evaluating drug-coated balloons is presented for reference. Overall, this article aims to provide clinicians and researchers with a comprehensive understanding of the current state of drug-coated balloon technology and its implications in clinical practice.</div></div>","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Pages 84-95"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146809","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Responses to the letter by Feka et al. regarding oral hydroquinidine as an alternative to intravenous quinidine","authors":"Redwane Rakza ,&nbsp;Pierre Groussin ,&nbsp;Karim Benali ,&nbsp;Nathalie Behar ,&nbsp;Philippe Mabo ,&nbsp;Dominique Pavin ,&nbsp;Christophe Leclercq ,&nbsp;Jackson J. Liang ,&nbsp;Raphaël P. Martins","doi":"10.1016/j.tcm.2024.09.001","DOIUrl":"10.1016/j.tcm.2024.09.001","url":null,"abstract":"","PeriodicalId":51199,"journal":{"name":"Trends in Cardiovascular Medicine","volume":"35 2","pages":"Page 139"},"PeriodicalIF":7.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142300360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}